XBiotech Inc. (XBIT) Plunges 8.34%

XBiotech Inc. (XBIT) Plunges 8.34%

XBiotech Inc. (XBIT) had a rough trading day for Tuesday November 26 as shares tumbled 8.34%, or a loss of $-1.05 per share, to close at $11.54. After opening the day at $12.43, shares of XBiotech Inc. traded as high as $12.58 and as low as $11.30. Volume was 368,956 shares over 2,852 trades, against an average daily volume of n/a shares and a total float of 41.01 million.

As a result of the decline, XBiotech Inc. now has a market cap of $473.27 million. In the last year, shares of XBiotech Inc. have traded between a range of $15.32 and $3.66, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

XBiotech Inc is an US based clinical-stage biopharmaceutical company which is engaged in discovering and developing True Human (antibody technology) monoclonal antibodies for treating a variety of diseases. The company focuses on developing MABp1 a therapeutic antibody as a treatment for cancer. It has developed therapeutic antibody Xilonix which is being evaluated as a monotherapy to treat advanced stages of colorectal cancer. Xilonix neutralizes a pro-inflammatory protein produced by leukocytes and other cells.

XBiotech Inc. is based out of Austin, TX and has some 59 employees. Its CEO is John Simard.

Scroll Up
error: Content is protected !!